CRISPR THERAPEUTICS AG
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M | $719.0K | $289.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $284.8M | $310.2M | $387.3M | $461.6M | $340.6M | $221.4M | $179.4M |
| SG&A Expense | — | $73.5M | $73.0M | $76.2M | $102.5M | $99.7M | $85.7M | $63.5M |
| Operating Income | — | $-664.6M | $-466.6M | $-222.5M | $-673.2M | $373.5M | $-354.4M | $46.7M |
| Operating Margin | — | -18,933.6% | -1,250.4% | -60.0% | -56,190.4% | 40.8% | -49,295.5% | 16.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-578.0M | $-362.7M | $-150.7M | $-650.5M | $379.5M | $-348.1M | $67.3M |
| Income Tax Expense | — | $3.6M | $3.6M | $2.9M | $-325.0K | $1.9M | $809.0K | $448.0K |
| Net Income | — | $-581.6M | $-366.3M | $-153.6M | $-650.2M | $377.7M | $-348.9M | $66.9M |
| Net Margin | — | -16,569.8% | -981.5% | -41.4% | -54,271.7% | 41.3% | -48,520.9% | 23.1% |
| EPS (Basic) | — | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 |
| EPS (Diluted) | — | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 |
| Shares Outstanding (Basic) | 96.0M | 89.9M | 84.4M | 79.2M | 77.7M | 75.9M | 65.9M | 54.4M |
| Shares Outstanding (Diluted) | 96.0M | 89.9M | 84.4M | 79.2M | 77.7M | 80.4M | 65.9M | 56.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |